Sera Prognostics, Inc. (SERA)
2.06
+0.03
(+1.48%)
USD |
NASDAQ |
Oct 16, 16:00
2.04
-0.02
(-0.97%)
After-Hours: 20:00
Sera Prognostics Research and Development Expense (Annual) : 12.35M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 12.35M |
| December 31, 2024 | 13.92M |
| December 31, 2023 | 14.32M |
| December 31, 2022 | 14.24M |
| Date | Value |
|---|---|
| December 31, 2021 | 11.02M |
| December 31, 2020 | 7.782M |
| December 31, 2019 | 9.353M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Myriad Genetics, Inc. | 106.80M |
| BioRestorative Therapies, Inc. | 10.09M |
| CareDx, Inc. | 71.43M |
| Natera, Inc. | 624.11M |
| Exagen, Inc. | 6.254M |